The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis.
Vaz Batista M, Pérez-García JM, Garrigós L, García-Sáenz JÁ, Cortez P, Racca F, Blanch S, Ruiz-Borrego M, Fernández-Ortega A, Fernández-Abad M, Iranzo V, Gion M, Martrat G, Alcalá-López D, Pérez-Escuredo J, Sampayo-Cordero M, Llombart-Cussac A, Braga S, Cortés J.
Vaz Batista M, et al. Among authors: cortes j.
Med. 2024 Sep 4:S2666-6340(24)00312-X. doi: 10.1016/j.medj.2024.08.001. Online ahead of print.
Med. 2024.
PMID: 39265579